AU2001237132B2 - A method of treatment - Google Patents
A method of treatment Download PDFInfo
- Publication number
- AU2001237132B2 AU2001237132B2 AU2001237132A AU2001237132A AU2001237132B2 AU 2001237132 B2 AU2001237132 B2 AU 2001237132B2 AU 2001237132 A AU2001237132 A AU 2001237132A AU 2001237132 A AU2001237132 A AU 2001237132A AU 2001237132 B2 AU2001237132 B2 AU 2001237132B2
- Authority
- AU
- Australia
- Prior art keywords
- lif
- disease
- day
- treatment
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000011282 treatment Methods 0.000 title claims description 44
- 238000000034 method Methods 0.000 title claims description 31
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 184
- 201000002491 encephalomyelitis Diseases 0.000 claims description 47
- 241000124008 Mammalia Species 0.000 claims description 23
- 238000011321 prophylaxis Methods 0.000 claims description 21
- 241001529936 Murinae Species 0.000 claims description 20
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims description 17
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 claims description 17
- 230000001154 acute effect Effects 0.000 claims description 8
- 241000282414 Homo sapiens Species 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000002981 neuropathic effect Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 claims description 5
- 102000046645 human LIF Human genes 0.000 claims description 5
- 201000001119 neuropathy Diseases 0.000 claims description 5
- 230000007823 neuropathy Effects 0.000 claims description 5
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 4
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 4
- 208000037187 Autoimmune Experimental Neuritis Diseases 0.000 claims description 3
- 230000003210 demyelinating effect Effects 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims description 3
- 102100032352 Leukemia inhibitory factor Human genes 0.000 claims 5
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 179
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 58
- 201000010099 disease Diseases 0.000 description 56
- 241000699670 Mus sp. Species 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 34
- 210000003169 central nervous system Anatomy 0.000 description 28
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 208000016192 Demyelinating disease Diseases 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 201000006417 multiple sclerosis Diseases 0.000 description 19
- 230000009467 reduction Effects 0.000 description 19
- 238000006722 reduction reaction Methods 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 239000003981 vehicle Substances 0.000 description 18
- 208000012902 Nervous system disease Diseases 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 230000003181 encephalopathic effect Effects 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 208000027866 inflammatory disease Diseases 0.000 description 15
- 239000000902 placebo Substances 0.000 description 15
- 229940068196 placebo Drugs 0.000 description 15
- 210000000278 spinal cord Anatomy 0.000 description 14
- 210000001428 peripheral nervous system Anatomy 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 10
- 101710142062 Leukemia inhibitory factor receptor Proteins 0.000 description 10
- 238000001114 immunoprecipitation Methods 0.000 description 10
- 210000003141 lower extremity Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000003393 splenic effect Effects 0.000 description 9
- 206010012305 Demyelination Diseases 0.000 description 8
- 206010033799 Paralysis Diseases 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000003827 upregulation Effects 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102000047918 Myelin Basic Human genes 0.000 description 5
- 101710107068 Myelin basic protein Proteins 0.000 description 5
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 5
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 210000004248 oligodendroglia Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000006386 Myelin Proteins Human genes 0.000 description 4
- 108010083674 Myelin Proteins Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000001668 ameliorated effect Effects 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- -1 coatings Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 208000032274 Encephalopathy Diseases 0.000 description 3
- 206010021118 Hypotonia Diseases 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 101000981991 Mus musculus Myelin proteolipid protein Proteins 0.000 description 3
- 101001135737 Mus musculus Parathyroid hormone-related protein Proteins 0.000 description 3
- 101000619799 Mus musculus Peroxiredoxin-5, mitochondrial Proteins 0.000 description 3
- 102000055324 Myelin Proteolipid Human genes 0.000 description 3
- 108700021862 Myelin Proteolipid Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 2
- DFVFTMTWCUHJBL-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-6-methylheptanoate Chemical compound CC(C)CC(N)C(O)CC(O)=O DFVFTMTWCUHJBL-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 230000021235 carbamoylation Effects 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 229950003349 emfilermin Drugs 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 208000010726 hind limb paralysis Diseases 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 229940100602 interleukin-5 Drugs 0.000 description 2
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 208000036546 leukodystrophy Diseases 0.000 description 2
- 208000027905 limb weakness Diseases 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- KMOUUZVZFBCRAM-OLQVQODUSA-N (3as,7ar)-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1C=CC[C@@H]2C(=O)OC(=O)[C@@H]21 KMOUUZVZFBCRAM-OLQVQODUSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- KFDPCYZHENQOBV-UHFFFAOYSA-N 2-(bromomethyl)-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1CBr KFDPCYZHENQOBV-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical class OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023163 JC virus infection Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 101150107363 Lif gene Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 101000930477 Mus musculus Albumin Proteins 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 150000007930 O-acyl isoureas Chemical class 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- AWGTVRDHKJQFAX-UHFFFAOYSA-M chloro(phenyl)mercury Chemical compound Cl[Hg]C1=CC=CC=C1 AWGTVRDHKJQFAX-UHFFFAOYSA-M 0.000 description 1
- VIMWCINSBRXAQH-UHFFFAOYSA-M chloro-(2-hydroxy-5-nitrophenyl)mercury Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[Hg]Cl VIMWCINSBRXAQH-UHFFFAOYSA-M 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000001712 encephalitogenic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 210000005230 lumbar spinal cord Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- SJFKGZZCMREBQH-UHFFFAOYSA-N methyl ethanimidate Chemical compound COC(C)=N SJFKGZZCMREBQH-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
WO 01/64239 PCT/AU01/00223 -1- A METHOD OF TREATMENT FIELD OF THE INVENTION The present invention relates generally to a method of treatment and to agents useful for same. More particularly, the present invention contemplates a method for the treatment and/or prophylaxis of a nervous system disease, demyelinating disease and/or an inflammatory disease of either the central or peripheral nervous system such as but not limited to an encephalopathic condition and even more particularly an encephalomyelopathic condition. The present invention further provides the use of leukemia inhibitory factor or derivatives, homologues or analogues thereof in the manufacture of a medicament for the treatment and/or prophylaxis of a nervous system disease, demyelinating disease and/or an inflammatory disease of either the central or peripheral nervous system such as but not limited to an encephalopathic and more particularly an encephalomyelopathic condition. Leukemia inhibitory factor may be used alone or in combination with one or more other therapeutic molecules such as but not limited to other cytokines. The method of the present invention enables the development of a therapeutic protocol for conditions such as multiple sclerosis, optic neuritis and other single episodes of central demyelination, transverse myelitis, HIV-induced leucoencephalopathy or chemotherapy induced leucoencephalopathy.
BACKGROUND OF THE INVENTION Reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in Australia or any other country.
Bibliographic details of the publications numerically referred to in this specification are collected at the end of the description.
WO 01/64239 PCT/AU01/00223 -2- Leukemia inhibitory factor (LIF) is a cytokine which exhibits a range of activities on a number of different cell types. For example, LIF is capable of maintaining embryonic stem (ES) cells in culture while retaining pluripotency. LIF is also capable of stimulating bone formation. Furthermore, LIF exhibits activity within the nervous and immune systems. For example, LIF promotes the survival of oligodendrocytes, the cells responsible for myelinating the central nervous system (CNS). It also acts as an anti-inflarmnatory and analgesic cytokine with the capacity to modulate expression of the pro-inflammatory cytokine, tumor necrosis factor-a (TNF-oa), as well as interleukin-6 LIF is, therefore, a pleiotropic molecule.
The subject inventors investigated the effects of LIF in other disease situations.
Experimental autoimmune encephalomyelitis (EAE) remains the most widely studied and informative of the experimentally induced models of autoiummune disease, and is the prototype for an antigen-specific and T cell-mediated attack on the target organ. There are two types of EAE, acute and chronic relapsing, depending on the species, the age of the animal and the nature of the encephalotigenic inoculum, amongst other factors.
The pathological similarities of multiple sclerosis (MS) to EAE also point to an autoimmune pathogenesis for MS. EAE can be induced in a variety of animal species by injection of myelin basic protein (MBP) or phospholipid protein (PLP) or peptides thereof, or by adoptive transfer of MBP- or PLP-specific CD4 T cells into naive recipients Acute EAE presents as a monophasic disease, characterised by inflammatory foci in the CNS with little or no demyelination. Chronic relapsing EAE (CREAE) is induced by immunisation with whole CNS tissue homogenate and, in contrast to acute EAE provoked by purified MBP and PLP, is characterized by focal demyelination in the CNS. Chronic relapsing EAE is considered to be a better animal model for MS because it induces the full spectrum of pathological changes characteristic of autoimmune demyelination The complexity of human autoimmune disease requires comparable models for a reductionist understanding of the aetiology, pathogenesis and for developing optimal WO 01/64239 PCT/AU01/00223 -3treatments. More than anything else, the routine production of EAE in mice and rats using myelin proteins such as MBP and PLP, has been an important development because it has became possible to test the efficacy of potential new therapeutic agents. p-Interferon and Copolymer-1, which are now used clinically for the treatment of MS, have both been shown to ameliorate EAE in rodents.
Specifically, p-interferon can reduce the severity of EAE when administered in a delayed paradigm under certain conditions in rats while Copolymer-1 is effective in preventing the induction of acute and chronic relapsing EAE induced by MBP and PLP in mice In work leading up to the present invention, the inventors determined that LIF has the capacity to abrogate experimental autoimmune encephalomyelitis. As stated above, the latter condition is an inflammatory disease of the CNS resulting from an autoimmune response to MBP or other myelin proteins including PLP. The consequence is brain and spinal cord invasion by immune cells and paralysis.
WO 01/64239 PCT/AU01/00223 -4- SUMMARY OF THE INVENTION Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.
One aspect of the present invention contemplates a method for the treatment and/or prophylaxis of a nervous system disease, demyelinating disease and/or an inflammatory disease condition of either the central or peripheral nervous system such as but not limited to an encephalopathic condition in a mammal, said method comprising administering to said mammal an effective amount of a polypeptide having leukemia inhibitory factor (LIF) properties or a derivative, homologue or analogue thereof for a time and under conditions sufficient to prevent or reduce onset of the condition or to ameliorate the symptoms of the condition.
Another aspect of the present invention is directed to a method for the treatment and/or prophylaxis of an encephalomyelopathic, myelopathic and/or a neuropathic condition in a mammal, said method comprising administering to said mammal an effective amount of a polypeptide having LIF properties or a derivative, homologue or analogue thereof for a time and under conditions sufficient to prevent or reduce onset of the condition or to ameliorate the symptoms of the condition.
A further aspect of the present invention contemplates a method for the treatment and/or prophylaxis of either experimental autoimmune encephalomyelitis or multiple sclerosis or a related or homologous disease condition such as a nervous system disease in a mammal, said method comprising administering to said mammal, an effective amount of LIF or a derivative, homologue or analogue thereof for a time and under conditions sufficient for the symptoms of the disease condition to be ameliorated.
WO 01/64239 PCT/AU01/00223 Still another aspect of the present invention contemplates a method for the treatment and/or prophylaxis of multiple sclerosis or a related or homologous disease condition in a mammal, said method comprising administering to said mammal, an effective amount of LIF or a derivative, homologue or analogue thereof for a time and under conditions sufficient for the symptoms of the disease condition to be ameliorated.
Yet another aspect of the present invention extends to the use of a polypeptide having LIF properties such as LIF or a derivative, homologue or analogue thereof in the manufacture of a medicament for the treatment and/or prophylaxis of a nervous system disease, demyelinating disease and/or an inflammatory disease of either the central or peripheral nervous system such as but not limited to an encephalopathic condition such as an encephalomyelopathic condition.
Even still another aspect of the present invention extends to a composition comprising a polypeptide having LIF properties for use in the treatment and/or prophylaxis of a nervous system disease, demyelinating disease and/or an inflammatory disease of either the central or peripheral nervous system such as but not limited to an encephalopathic condition such as an encephalomyelopathic condition, said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents.
Even yet another aspect of the present invention extends to an agent comprising a polypeptide having LIF properties for use in the treatment and/or prophylaxis of a nervous system disease, demyelinating disease and/or an inflammatory disease of either the central or peripheral nervous system such as but not limited to an encephalopathic condition such as an encephalomyelopathic condition, said agent further comprising one or more pharmaceutically acceptable carriers and/or diluents.
WO 01/64239 PCT/AU01/00223 -6- BRIEF DESCRIPTION OF THE FIGURES Figure 1 is a graphical representation showing the effect of various doses of LIF and EAE severity. Mean disease scores, LIF versus vehicle. LIF was administered daily on days 0- 18. Day 18 contro versus LIF 25 Jg/kg p 0.01. Error bars showed standard errors.
Figure 2 is a graphical representation showing mean disease scores, LIF versus vehicle (placebo; murine serum albumin LIF was administered daily on days 0-18. Day 18 p 0.01, n 18 per group. Error bars show standard errors.
Figure 3 is a graphical representation showing the cumulative probability of death following treatment with mice with LIF from day 0 to day 18.
Figure 4 is a graphical representation showing mean disease scores, LIF versus vehicle (placebo; MSA). Mice were divided into two groups with equal disease severity on day 12.
LIF was administered daily on days 12-24. Day 24 p 0.03, n 20 per group. Error bars show standard error.
Figure 5 is a graphical representation showing the temperal cumulative probability of death in placebo (MSA) versus LIF treated animals.
Figure 6 are two histograms showing proliferation on splenic mononuclear cells in the presence of 2, 10 and 25 gg/kg of LIF or MSA after 48 and 72 hrs of culture.
ave nil, average nil (no treatment) S= ave PLP (4 gg), average 4 gg PLP treatment S= ave PLP (20 jg), average 20 gg PLP treatment IL-2 (100 U/ml), average 100 U/ml IL-2 treatment WO 01/64239 PCT/AU01/00223 -7- Figure 7A is a graphical representation showing the effect of various doses of LIF on EAE severity. Mean disease scores, LIF versus vehicle (MSA). LIF was administered daily on days 0-18. Day 18 control versus LIF 25 ptg/kg p<0.01. Error bars show standard errors.
Figure 7B is graphical representation showing the effect of 60 pg/kg/day LIF on EAE severity. Mean disease scores, LIF versus vehicle (MSA). LIF was administered daily on days 0-18. Error bars show standard errors.
Figure 8 are two histograms showing proliferation assays of cultured spleenocytes. Effect of prior exposure to various concentrations of LIF for 12 days. 48 hours of culture and 72 hours of culture no treatment I PLP at 4 gg PLP at 20 pg Figure 9 is a photographic representation showing embryonic day 18 murine cortex lysates demonstrate the specificity of the polyclonal anti-LIFR-beta antibody. Knockout mice show no band at 190kD, and the signal obtained from heterozygotes is approximately half the strength of that obtained from the wild-type animals Adult cortex demonstrates continues expression of the receptor.
Figure 10 is a photographic representation showing adult mouse cerebellum/brainstem lysates demonstrate the specificity of the polyclonal anti-gpl30 antibody. Lysate from the relevant adult knockout mouse (gpl30 STAT-3 deletion mutant, deleting the site against which the Ab is raised) shows no signal at 130kD, in contrast to the littermate wildtype control which is postive.
Figure 11 is a photographic representation showing expression levels of gpl30 (left) and LIFR-beta (right) from spinal cord lysates obtained from LIF and vehicle treated EAE WO 01/64239 PCT/AU01/00223 -8animals compared with non-disease controls Gpl30 expression is invariate. EAE results in marked upregulation of LIFR-.
Figure 12 is a graphical representation showing expression levels of STAT-3 (top panel) and Phospho-STAT-3 (bottom panel) from the same experiment as Figure 11. Basal STAT-3 levels are low and not upregulated in the context of early EAE. LIF treatment results in marked upregulation of STAT-3 and detectable levels of Phospho-STAT-3.
Figure 13 is a graphical representation showing the mean disease scores from dose range finding study, LIF versus vehicle. Mice were divided into three groups with equal disease severity on day 14-16. LIF was then administered daily for 40 days. Day 56, p=0.01 control versus LIF 25 jg/kg; p=0.04 control versus LIF 10 ig/kg. Error bars show standard error.
Figure 14 is a graphical representation showing mean disease scores from main studay, LIF versus vehicle. Mice were divided into three groups (n=15 per group) with equal disease severity on day 16-1. LIF was then administered daily by subcutaneous injection for 50 days. Day 60, p=0.06 control versus LIF 25 ig/kg;. Error bars show standard error.
WO 01/64239 PCT/AU01/00223 -9- The following abbreviations are used in the specification:- Abbreviation Definition CNS Central nervous system CREAE Chronic relapsing EAE EAE Experimental autoimmune encephalitis ELISA Enzyme linked immunosorbent assay ES Embryonic stem cells H37Ra Strain of Mycobacterium tuberculosis IL-2 Interleukin-2 IL-6 Interleukin-6 LIF Leukemia inhibitory factor 1 MBP Myelin basic protein mcg Microgram MS Multiple sclerosis MSA Murine serum albumin PLP Proteolipid protein TNF-a Tumor necrosis factor-a Emfilermin is the World Health Organization approved name for the pharmaceutical form of recombinant human LIF produced in E. coli in a manner that makes it suitable for human clinical use. Emfilermin is formulated in an aqueous buffer at low pH and is suitable for subcutaneous injection.
WO 01/64239 PCT/AU01/00223 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention is predicated in part on the determination that LIF has the capacity to abrogate disease conditions of nervous systems.
Accordingly, one aspect of the present invention contemplates a method for the treatment and/or prophylaxis of a nervous system disease, demyelinating disease and/or an inflammatory disease condition of either the central or peripheral nervous system such as but not limited to an encephalopathic condition in a mammal, said method comprising administering to said mammal an effective amount of a polypeptide having leukemia inhibitory factor (LIF) properties or a derivative, homologue or analogue thereof for a time and under conditions sufficient to prevent or reduce onset of the condition or to ameliorate the symptoms of the condition.
The present invention extends to any encephalopathic, neuropathic or myelopathic condition. Such conditions may be induced by autoimmune mechanisms or may be induced by an infectious agent or chemical toxicant or induced following radiation therapy or chemotherapy or may be idiopathic. Examples of autoimmune encephalopathy, myelopathy and neuropathy include conditions exacerbated by an autoimmune response to myelin proteins. This is postulated to occur in experimental autoimmune neuritis, encephalomyelitis, multiple sclerosis and neuropathic acute demyelinating neuropathies Guillian Barrc syndrome) and chronic inflammatory demyelinating polyneuropathy.
Pathogenic-induced encephalopathy includes microbial encephalitis, viral encephalitis, post-infectious encephalopathy and as well as progressive multi-focal leucoencephalopathy due to JC virus infection. The present invention also extends to genetic conditions such as leucodystrophies.
Reference herein to "nervous system disease" includes reference to encephalopathic, myelopathic or neuropathic conditions.
WO 01/64239 PCT/AU01/00223 -11- It is a particular aspect of the present invention to treat encephalomyelitis such as but not limited to encephalomyelitis and multiple sclerosis.
Accordingly, another aspect of the present invention is directed to a method for the treatment and/or prophylaxis of an encephalomyelopathic, myelopathic and/or a neuropathic condition in a mammal, said method comprising administering to said mammal an effective amount of a polypeptide having LIF properties or a derivative, homologue or analogue thereof for a time and under conditions sufficient to prevent or reduce onset of the condition or to ameliorate the symptoms of the condition.
A "polypeptide having leukemia inhibitory factor properties" means LIF or a derivative or homologue thereof or a fusion or hybrid protein comprising all or a portion of LIF or its derivative or homologue or an analogue of LIF. Generally, the polypeptide having LIF properties exhibits at least one activity associated with LIF and in the present case is capable of ameliorating the effects of a nervous system disease, demyelinating disease and/or an inflammatory disease of either the central or peripheral nervous system such as but not limited to an encephalomyelopathic condition such as either experimental autoimmune encephalomyelitis or multiple sclerosis.
In a particularly preferred embodiment, the polypeptide is mammalian LIF such as but not limited to human, primate, murine or livestock animal LIF. Reference herein to "LIF" or its full name "leukemia inhibitory factor" includes reference to its derivatives, homologues and analogues. LIF is well described in International Patent Application No.
PCT/AU88/00093.
Generally, the present invention relates to the treatment of a disease condition which becomes apparent following the development of symptoms or through biochemical or genetic testing or following neuroimaging MRI scan). However, where a risk has been identified of developing a nervous system disease, demyelinating disease and/or an inflammatory disease of either the central or peripheral nervous system such as but not limited to an encephalopathic condition, then the administration of a polypeptide having WO 01/64239 PCT/AU01/00223 -12- LIF activity including LIF is indicated to reduce the likelihood of development of the condition. A risk of development of the disease may be determined genetically such as by way of a genetic predisposition to the condition or following infection by an agent known to cause encephalitis. Accordingly, the present invention extends to the treatment and prophylaxis of a nervous system disease, demyelinating disease and/or an inflammatory disease of either the central or peripheral nervous system such as but not limited to an encephalopathic condition.
The present invention contemplates the treatment and/or prophylaxis of mammals.
Reference herein to mammals includes humans, primates, livestock animals sheep, horses, cows, pigs, donkeys), laboratory test animals mice, rats, rabbits, guinea pigs, hamsters), companion animals dogs, cats) and captured wild animals. In an alternative embodiment, the subject is a murine animal with, for example, experimental autoimmune encephalomyelitis. Such an animal is a useful murine model for encephalomyelopathic conditions such as multiple sclerosis.
In a particularly preferred embodiment, the present invention contemplates a method for the treatment and/or prophylaxis of either experimental autoimmune encephalomyelitis or multiple sclerosis or a related or homologous disease condition such as a nervous system disease in a mammal, said method comprising administering to said mammal, an effective amount of LIF or a derivative, homologue or analogue thereof for a time and under conditions sufficient for the symptoms of the disease condition to be ameliorated.
An example of a disease condition related or homologous to experimental autoimmune encephalomyelitis is multiple sclerosis As stated above, however, the present invention extends to all nervous system disease conditions such as acute and chronic demyelination neuropathies Guillian Barre syndrome) or chronic inflammatory demyelinating polyneuropathy as well as central nervous system demyelination and radiation and/or chemotherapy-induced leucoencephalopathy as well as genetically determined conditions causing demyelination including but not restricted to the leucodystrophies.
WO 01/64239 PCT/AU01/00223 -13- Preferably, the mammal is a human or a laboratory test animal.
Accordingly, in a particularly preferred embodiment, the present invention contemplates a method for the treatment and/or prophylaxis of MS or a related or homologous disease condition in a mammal, said method comprising administering to said mammal, an effective amount of LIF or a derivative, homologue or analogue thereof for a time and under conditions sufficient for the symptoms of the disease condition to be ameliorated.
The present invention further extends to the use of a polypeptide having LIF properties such as LIF or a derivative, homologue or analogue thereof in the manufacture of a medicament for the treatment and/or prophylaxis of a nervous system disease, demyelinating disease and/or an inflammatory disease of either the central or peripheral nervous system such as but not limited to an encephalopathic condition such as an encephalomyelopathic condition.
The method and use according to these and other aspects of the present invention may comprise the administration of LIF alone or in combination with one or more other therapeutic agents such as but not limited to one or more other cytokines. The additional agents may be administered simultaneously or sequentially with LIF. Sequential administration means separate administrations within seconds, minutes, hours, days or weeks of LIF and the other agent. LIF and the other agent or agents may be administered in any order. Particularly useful other agents include interferon-3, steroids, methotrexate and/or other immunosuppressive agents used in the treatment of encephalopathic conditions.
The present invention further extends to a composition comprising a polypeptide having LIF properties for use in the treatment and/or prophylaxis of a nervous system disease, demyelinating disease and/or an inflammatory disease of either the central or peripheral nervous system such as but not limited to an encephalopathic condition such as an WO 01/64239 PCT/AU01/00223 14encephalomyelopathic condition, said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents.
Reference to a composition includes reference to an agent.
Accordingly, the present invention further extends to an agent comprising a polypeptide having LIF properties for use in the treatment and/or prophylaxis of a nervous system disease, demyelinating disease and/or an inflammatory disease of either the central or peripheral nervous system such as but not limited to an encephalopathic condition such as an encephalomyelopathic condition, said agent further comprising one or more pharmaceutically acceptable carriers and/or diluents.
Preferably, the composition is exclusively used for the treatment and/or prophylaxis of the conditions.
Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
The pharmaceutical composition may also comprise genetic molecules such as a vector capable oftransfecting target cells where the vector carries a nucleic acid molecule capable of modulating expression of a nucleic acid molecule encoding binding partner. The vector may, for example, be a viral vector. In this regard, a range of gene therapies are contemplated by the present invention including isolating certain cells, genetically manipulating and returning the cell to the same subject or to a genetically related or similar subject. The present invention further contemplates the administration of "naked" DNA which encodes a LIF polypeptide or an agonist of expression of a LIF gene.
WO 01/64239 PCT/AU01/00223 LIF may be administered in any number of ways including via intravenous, intraperitoneal, subcutaneous, intrathecal, rectal, intranasal or aerosol administration. Prolonged infusion or sustained release administration is also contemplated. Preparations comprising LIF can be conveniently prepared with reference to Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, U.S.A.
As stated above, the present invention extends to LIF and its derivatives, homologues and analogues. A derivative includes a mutant, fragment, part, portion or region of LIF such as a single or multiple amino acid substitution, addition and/or deletion to the LIF amino acid sequence. A derivative also includes hybrid molecules and fusion molecules such as between LIF polypeptides from different species of animals or between polymorphic variants of LIF polypeptides within the one species.
Other derivatives of LIF contemplated by the present invention include a range of glycosylation variants from a completely unglycosylated molecule to a modified glycosylated molecule. Altered glycosylation patterns may result from expression of recombinant molecules in different host cells.
A "homologue" includes a LIF molecule from a different animal species as well as a structurally and/or functionally related molecule from the same species. A polymorphic variant is regarded herein as a homologue.
LIF "analogues" contemplated herein include but are not limited to modifications to side chains, incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecule or their analogues.
Analogues may exhibit greater stability, longer serum half-life and enhanced efficacy.
Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an WO 01/64239 PCT/AU01/00223 -16aldehyde followed by reduction with NaBH 4 amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH 4 The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.
The carboxyl group may be modified by carbodiimide activation via O-acylisourea formation followed by subsequent derivitization, for example, to a corresponding amide.
Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.
Tryptophan residues may be modified by, for example, oxidation with Nbromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.
Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.
WO 01/64239 PCT/AU01/00223 -17- Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids.
Crosslinkers can be used, for example, to stabilize 3D conformations, using homobifunctional crosslinkers such as the bifunctional imido esters having (CH 2 )n spacer groups with n=1 to n=6, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of Ca and N -methylamino acids, introduction of double bonds between Ca and C3 atoms of amino acids and the formation of cyclic peptides or analogues by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.
All derivatives, homologues and analogues of LIF are encompassed by the terms "leukemia inhibitor factor", "LIF", "LIF polypeptide" and a "polypeptide having LIF properties".
The effective amount of LIF contemplated for use in accordance with the subject method in the amount required to ameliorate the symptoms of the encephalopathic condition.
Suitable amounts may need to be varied according to the condition and severity of the condition being treated. Multiple doses may be administered or a single bolus may be given. Examples of effective amounts include from about 10 ng/kg body weight to about mg/kg body weight and more particularly from about 0.1 tg/kg body weight to about mg/kg body weight and even more particularly from about 0.5 /tg/kg body weight to about 1 mg/kg body weight. Administration may be per hour, per day, per week, or per month.
Generally, recombinant LIF is administered. For the treatment of humans, for example, WO 01/64239 PCT/AU01/00223 18recombinant human LIF is preferred although the present invention extends to humanized forms of non-human LIF.
The present invention is further described by the following non-limiting Examples.
WO 01/64239 PCT/AU01/00223 -19- EXAMPLE 1 Effect ofLIF on experimental autoimmune encephalomyelitis I Female 7-10 week old SL/J mice were immunized with 100 /pg of serine-substituted peptide from mouse PLP (amino acids 139-151) dissolved in 0.1 ml phosphate-buffered saline (PBS) emulsified with an equal volume of complete Freund's adjuvant, containing Mycobacterium tuberculosis H37Ra (4 mg/ml). Mice were also given 400 ng of pertussis toxin into the tail vein on the day of inoculation and 3 days later. This particular model results in severe monophasic EAE. Murine LIF in 0.3% v/v mouse serum albumin [MSA], pH 7.4. (Sigma) was intraperitoneally administered daily on day 0-18. The initial study was conducted to determine approximate dose ranges. Three cohorts of mice received 2, or 25 /g/kg of LIF, respectively and mice injected with MSA alone served as controls. The severity of disease was evaluated daily using the following scale: 0, no clinical symptoms; 1, fur ruffling and/or distal tail weakness; 2, tail atonia and/or slight hind limb paralysis; 3, complete paralysis affecting both hind limbs; 4 complete paralysis of both hind limbs and fore-limb weakness. Statistical comparisons between groups were perfonred using the unpaired two-tailed Student's t-test.
Splenic mononuclear cell suspensions were prepared from mice 12 days after inoculation.
As an indirect marker of lymphocyte activation, the proliferation index of the cells was assessed in either PLP peptide (4 or 20 pg/ml) or interleukin-2 (20 IU/ml) by measuring 3H-thymidine incorporation after a 2 day culture period and a 16 hour pulse. The ratio of CD4 to CD8 positive cells in the spleen was assessed at the same timepoint by FACS.
Western blot of immunoprecipitate of CNS lysates was performed according to standard methods. The gpl30 antibody used was the polyclonal rabbit-anti-mouse sc-656 antibody (Santa Cruz). Specificity of the signal was determined by the use of CNS tissue from a mouse in which the gpl30 receptor has been truncated as a control. The truncation removes the domain against which the antibody was raised.
WO 01/64239 PCT/AU01/00223 The groups of mice receiving 25 /g/kg of LIF showed a reduction of experimental autoimmune encephalomyelitis (EAE) disease score compared with the placebo groups On day 18 post-induction, the mean disease score in the LIF treated mice was 1.8 compared with 3.2 in the placebo cohort (p<0.01) [Figure The death rate at day 18 was 67% in the placebo group, compared with 33% in the LIF treated group. Animals treated with lower doses of LIF (2 pg/kg and 10 jg/kg) showed no significant disease reduction (Figure LIF did not retard the onset of disease.
Since the initial study produced promising results, the effect of LIF in this model of MS was then examined in greater detail. This focussed on strengthening the data in the high dose LIF group.
Two cohorts of mice were used to confirm the above data which showed that high dose LIF (25 ag/kg/day) was able to slow the progression of EAE when administered from day 0-18. This was performed as described in the previous section for the pilot study.
The cohort that received LIF exhibited a significant reduction in disease score from day 18 when compared to the vehicle group [Figure On day 18, the average disease score in the LIF treated group was 2.6 compared with 3.6 in the vehicle group (p 0.01). By day 24, 78% of the animals receiving vehicle had died, compared with 50% of LIF treated animals. This is shown in the cumulative probability of death shown in Figure 3.
A further two cohorts of mice were utilized in order to determine whether LIF at tlg/kg/day given after disease onset could alter the subsequent course of disease. Inoculated animals were randomized on day 12 into two groups (total n=29 in each group), matched on their neurological grade and the amount of weight loss in the preceding 24 hours. LIF Mg/kg) or MSA were administered IP from day 12 to 24. Matching by grade was successful as indicated by a nearly identical average EAE score on the first day after matching (day 13). The cohort that received LIF exhibited a significant reduction in disease score from day 17. On day 24, the average disease score in the LIF treated group WO 01/64239 PCT/AU01/00223 -21was 2.4, compared with 3.1 in the placebo group (p<0.03) [Figure By day 24, 80% of placebo animals had died, compared with 45% of LIF treated animals [Figure EXAMPLE 2 Immunological assessments The percentage of splenic white cells expressing CD4 and CD8 collected on day 12 after disease induction, as assessed by FACS sorting, were similar in MSA and LIF treated animals, at all doses of LIF examined 10, 25 j/g/kg).
Thymidine incorporation assays of the same spleen cells yielded potentially interesting results at a culture density of 2 x 105 cells/well, at both 48 and 72 hours of culture.
Specifically, there was a reduction of non-selective proliferation (IL-2 induced) of splenic cells collected from animals exposed to low dose LIF compared with those exposed to either MSA or higher doses of LIF. However, there was a trend towards enhanced proliferation in response to PLP (the induction antigen) in the animals treated with LIF, in a dose-dependent manner [Figure These results are further analyzed confirm the above results by repeating the experiment and to measure cytokine profiles of the proliferating cells in response to PLP stimulation. This enables characterization of the response as pro-inflammatory or anti-inflammatory. However, it is likely that LIF exerts some effect upon splenic mononuclear cells. The clinical data show that this effect is not deleterious in the context of EAE.
EXAMPLE 3 Expression of the LIF receptor components GP130 and LIF receptor in the CNS The inventors have demonstrated definite expression of the gpl30 component of the receptor in the adult murine cerebellum and brainstem by Western blot immunoprecipitation. The gpl30 component cannot be visualized by a straight Western blot of lysate, but is easily demonstrated by immunoprecipitation. Results indicated that WO 01/64239 PCT/AU01/00223 -22there was no change in the amount of gpl30 expression in EAE animals compared with controls.
Results suggested that the LIF-receptor 3 component is also detectable by immunoprecipitation Western blot.
EXAMPLE 4 Delayed administration ofLIF The experiment outlined in Example 1 is repeated to confirm the efficacy of delayed administration. Similar results as outlined in the third cohort of mice in Example 1 are anticipated.
EXAMPLE Cytokine production Splenic mononuclear cells are removed at day 12 post-induction of experimental autoimmune encephalomyelitis and cultured. ELISA and/or other immunodiagnostic procedures are then used to determine the cytoldne profile. Of particular interest is the determination of whether levels of interferon-7 or IL-6 change. This enables the potential effects of LIF on the cytokine profile to be determined.
EXAMPLE 6 Oligodendrocytes The numbers of oligodendrocytes in experimental autoimmune mice are determined relative to control mice in the lumbar spinal cord. A difference would indicate that LIF has an effect on oligodendrocyte survival and/or regeneration.
WO 01/64239 PCT/AU01/00223 -23- EXAMPLE 7 LIF receptor Murine CNS tissue from experimental autoimmune encephalomyelitis relative to control mice is subjected to Gpl30 staining. This enables an assessment to be made of the potential upregulation of the LIF receptor signalling components in the context of EAE, providing a potential mechanism by which the therapeutic effects of LIF might be mediated in the context of CNS inflammatory disease.
EXAMPLE 8 Combination therapy The experiment outlined in Example 1 is repeated with LIF and interferon-0 being administered simultaneously and sequentially in either order. Greater efficacy for the combination than with either agents alone is indicative of synergy and the potential value of combination therapy.
EXAMPLE 9 Effect of LIF on experimental autoimmune encephalomyelitis II The study described in Example 1 was then extended to test a higher dose of LIF. Two groups of mice were used; one received LIF at 60 jig/kg/day, while the second served as the control group.
Female 7-14 week old SJL/J mice were immunized with 100 ptg of serine-substituted peptide from mouse PLP (amino acids 139-151) dissolved in 0.1 ml of phophate-buffered saline emulsified with an equal volume of complete Freund's adjuvant, containing Mycobacterium tuberculosis H37Ra (4 mg/ml). Mice were also given 400 ng of pertussis toxin into the tail vein on the day of inoculation and 3 days later. This particular model resulted in severe monophasic EAE.
WO 01/64239 PCT/AU01/00223 -24- Murine LIF in 0.3% w/v MSA (Sigma) was administered daily intraperitoneally on day 0- 18. The severity of disease (clinical score) was evaluated daily using the following scale: 0 no clinical symptoms; 1 fur ruffling, and/or distal tail weakness; tail weakness and slight hindlimb weakness; 2 tail atonia, and/or slight hind limb paralysis; tail atonia and significant incomplete hindlimb weakness; 3 complete paralysis affecting both hind limbs; 4 complete paralysis of both hind-limbs and fore-limb weakness.
Statistical comparisons between groups were performed using the unpaired two-tailed Student's t-test.
The group of mice receiving 25 pg/kg of LIF again showed a reduction of EAE disease score compared with the placebo (MSA) groups On day 18 post-induction, the mean disease score in the LIF treated mice was 1.8 compared with 3.2 in the placebo (MSA) cohort (p<0.01) [Figure 7A]. The death rate at day 18 was 67% in the placebo (MSA) group, compared with 33% in the LIF treated group. Animals treated with lower doses of LIF (2 tg/kg and 10 pg/kg) showed no significant disease reduction. LIF did not retard the onset of disease. The mice that received LIF at 60 ig/kg/day also showed a significant reduction in EAE (clinical) score. However, this group performed no better than the group that received LIF at 25 gg/kg [Figure 7B].
EXAMPLE Immunological assessments from Example 9 An immunological assessment from the mice of Example 9 was tested as described in Example 2.
WO 01/64239 PCT/AU01/00223 The percentage of splenic white cells expressing CD4 and CD8 collected on day 12 after disease induction, as assessed by FACS sorting, were similar in MSA and LIF treated animals at all doses of LIF examined 10, 25 [tg/kg). After 72 hours of culture, splenocytes derived from LIF treated animals showed a non-significant reduction in total proliferation index, correlating with a 20% reduction in both CD4 and CD8 lymphoyte contents.
Cytokine levels of interferon-y, interleukin-12, interleukin-5 and interleukin-10 in mixed splenocyte cultures were assessed by ELISA. Production of these cytokines were similarily all modestly reduced in the cultures derived from LIF-treated animals compared with the vehicle treated group. The results are shown in Figure 8.
EXAMPLE 11 Expression of LIF receptor and the STAT3 signalling molecule in the CNSfrom Example 9 For assessment of potential central actions of LIF, animals which had received 25|pg/kg of LIF daily from day 0 were killed on day 12 (day of overt disease onset). Spinal cords were obtained by saline-flush. Immunoprecipitation (IP) of lysed spinal cord was performed with Protein G beads and the samples were liberated from the beads under reducing conditions. They were then run on 4-20% w/v polyacrylamide gels. The gels were transferred onto appropriate membranes and Western blotting with chemiluminescent detection was used to assess for the presence and levels of components of the cognate LIF receptor, namely gpl30 and LIF receptor-P. Both polyclonal rabbit-anti-mouse antibody used were tested for specificity using the relevant deletion mutants. The inventors also assessed the levels of the major downstream signalling protein activated by the LIF receptor complex, STAT3, and its activated form, TYR-phosphorylated STAT3, by immunoprecipitation/Westem blotting.
Gpl30 and LIFR-beta polyclonal antibody were specific, as demonstrated by analysis of the relevant knock-out CNS tissues [Figures 9 and 10]. LIFR-3 could not be demonstrated WO 01/64239 PCT/AU01/00223 -26in the control spinal cord on this occasion, but EAE resulted in marked upregulation of the LIFR-3 component. [Figure 11] Gpl30 was present in normal adult murine spinal cord, and levels did not change with EAE induction or LIF treatment. Data from subsequent experiments suggest that, under control conditions, a basal LIFR-3 expression is sometimes detectable in the adult murine spinal cord, but LIFR-fl levels are always upregulated in EAE.
LIF administration results in marked upregulation of STAT-3 levels in the spinal cord.
Basal levels were low and not changed in EAE animals treated with vehicle. Additionally, STAT-3 activation as determined by detectable levels of phosphorylated STAT-3 in the cord were detected only in animals treated with LIF [Figure 12].
EXAMPLE 12 Effect of LIF on experimental autoimmune encephalomyelitis III LIF was further tested for its capacity to abrogate experimental autoimmune encephalomyelitis in the murine model of multiple sclerosis.
An initial study was again conducted as a dose range finding study and examined the effect of 2 different doses of LIF. Two cohorts of mice received 10 or 25 gg/kg of LIF respectively and mice injected with MSA (LIF was formulated in PBS pH 7.4 0.1% mouse albumin which served as a carrier protein) alone served as controls.
Female 8-10 week old C57BL/6 mice were injected subcutaneously into one hind footpad and into the back of the neck (50 p.l each) with 100 pig of peptide from mouse myelin oligodendrocyte protein [MOG] (amino acids 35-55), dissolved in 50 p.l of PBS and emulsified with an equal volume of complete Freund's adjuvant containing Mycobacterium tuberculosis (4 mg/ml). Mice were then injected intravenously with pertussis vaccine (300 ng in 0.3m 1 PBS). Pertussus injection was repeated 48 hr later. This particular model results in a chronic progressive EAE.
WO 01/64239 PCT/AU01/00223 -27- Murine LIF in 0.1% w/v MSA (Sigma) was administered daily subcutaneously for 40 days, beginning at the time clinical symptoms become evident, usually at day 14-16. Clinical impairment was graded daily using the following scale: 0 no detectable impairment 1 limp tail and loss of weight 2 weakness of hindlimbs 3 complete paralysis of one/both hind limbs 4 complete paralysis of one/both hind-limbs and ascending paralysis. At this stage mice are considered moribound and must be euthanased deceased Statistical comparisons between groups were performed using the unpaired two-tailed Student's t-test.
As this was a preliminary study, only five animals were used per group. Fourteen out of mice developed clinical signs of EAE after-immunization and were used in the study. Five mice were assigned to each of the two LIF treatment groups and 4 mice were used in the control group. One mouse from the high dose LIF group died on day 28 and was excluded from the analysis from that point onwards. The death was not considered treatment or disease related.
The group of mice receiving 25 gg/kg of LIF showed a reduction of EAE disease score compared with the vehicle group. On day 56 post-induction the mean disease score in the high dose LIF group was 0.4 compared with 1.3 in the vehicle cohort (p=0.01) [Figure 13].
Mice treated with LIF at 10 rig/kg also showed a reduction in mean clinical score compared to the control group which was also significant (p=0.0 4 The mortality at day 56 was in the control group, while no mice had died in either of the two LIF treatment groups.
Since the above study again produced promising results, the effect of LIF in this model of EAE was then examined in greater detail. This focussed on strengthening the data in both WO 01/64239 PCT/AU01/00223 -28the 10 and 25 jg/kg dose groups. Inoculated animals were randomised on day 16-18 into two groups (total n=15 in each group), matched on their neurological grade. LIF 10 and g/kg or vehicle (MSA) was then administered subcutaneously once daily for 50 days.
The cohort that received LIF at a dose of 25 gg/kg exhibited a significant reduction in disease score, with the effect being observed beginning at about day 40. By day 65, the average disease score in the high dose LIF group was 1.9 compared with 3.1 in the vehicle treated group The cohort that received LIF at 10 lg/kg also showed a reduction in mean clinical score compared to control group. However, this was less significant than the high dose LIF group [Figure 14].
There was also a dose-related reduction in mortality observed. On day 65, 40% of the mice in the vehicle group had died. The mortality was reduced to 33% in the low dose LIF group, while only 20% of the mice in the high dose group had died by the end of the study.
At the termination of the study the mice were killed, blood was sampled and the spleens removed. Antibody activity to MOG or MOG peptide is measured in serum by ELISA according to standard protocols. Spleenocytes are cultured and assayed for T-cell, antibody and cytokines responses. Brain and spinal cord are also removed for histological analysis to assess the degree of inflammation, demyelination and/or remyelination.
EXAMPLE 13 Leukaemia inhibitory factor reduces the severity of murine experimental autoimmune encephalomyelitis The potential of LIF as a treatment for the murine model of inflammatory central nervous system disease was further tested.
SJL/J mice were immunised with an encephalitogenic portion of mouse PLP in complete Freund's adjuvant. Murine LIF was administered daily on days 0-18, in doses of 2, 10, and 60 gg/kg to determine the optimum dose. Subsequently, LIF (25 m/kg) was WO 01/64239 PCT/AU01/00223 -29administered on days 0-18 or days 12-24 (delayed treatment groups were matched for grade of disease and weight loss), whilst control mice were injected with albumin. The relapse rate was measured up to day 60 post induction in mice treated with LIF jg/kg/day) between either day 12-24 or day 12-60, and with placebo. Disease was scored using a non-parametric scale. For immunological assessments, splenic mononuclear cell suspensions were prepared from mice 12 days after inoculation, cultured at equal density for 72 hours in RPMI and the proliferation index of the cells was assessed in either PLP peptide, interleukin-2, or both, utilizing tritiated thymidine incorporation. Lymphocyte numbers and the CD4/CD8 T-lymphocyte ratio in the spleen were assessed at day 12 by fluorescence-activated cell sorting, and also after 72 hour culture. Cytokine levels of interferon-y, interleukin-12, interleukin-5 and interleukin-10 in mixed splenocyte cultures were assessed by ELISA.
For assessment of potential central actions of LIF, animals which had received 25 [ig/kg of LIF daily from day 0 were killed on day 12 (day of overt disease onset). Spinal cords were obtained by saline-flush. Immunoprecipitation (IP) of lysed spinal cord was performed with Protein G beads and the samples were liberated from the beads under reducing conditions. They were then run on 4-20% w/v polyacrylamide gels. The gels were transferred on to appropriate membranes and Western blotting with chemiluminescent detection was used to assess for the presence and levels of components of the cognate LIF receptor, namely gp 130 and LIF receptor-3. Both polyclonal rabbit-anti-mouse Ab used were tested for specificity using the relevant deletion mutants. The subject inventors also assessed the levels of the major downstream signalling protein activated by the LIF receptor complex, STAT3, and its activated form, TYR-phosphorylated STAT3, by immunoprecipitation/Western blotting.
The optimum dose of LIF was 25 ug/kg/day. Mice receiving this dose of LIF from day 0- 18 had abrogated disease, such that on day 18, the mean disease score was 2.6 compared with 3.6 in the placebo cohort LIF did not retard the time of onset of disease. In the delayed treatment group, LIF reduced mean disease grade on day 24 from 3.1 to 2.4 In contrast, the relapse rate was not affected by treatment. The numbers of WO 01/64239 PCT/AU01/00223 splenic CD4 and CD8 positive cells were similar in both LIF-treated and control groups.
After 72 hours of culture, splenocytes derived from LIF treated animals showed a nonsignificant reduction in total proliferation index, correlating with a 20% reduction in both CD4 and CD8 lymphoyte contents. Production of interferon-, IL-5, and IL-10 were similarily all modestly reduced in the cultures derived from LIF-treated animals compared with placebo.
Gp130 and LIFR-3f polyclonal Ab were specific, as demonstrated by analysis of the relevant knock-out CNS tissues. LIFR-0 could not be demonstrated in the control spinal cord on this occasion, but EAE resulted in marked upregulation of the LIFR-3 component.
Gp130 was present in normal adult murine spinal cord, and levels did not change with EAE induction or LIF treatment. Data from subsequent experiments suggest that, under control conditions, a basal LIFR-j3 expression is sometimes detectable in the adult murine spinal cord, but LIFR-3 levels are always upregulated in EAE.
LIF administration results in marked upregulation of STAT-3 levels in the cord. Basal levels are low and not changed in EAE animals treated with placebo (MSA). Additionally, STAT-3 activation as determined by detectable levels of phosphorylated STAT-3 in the cord can be shown only in animals treated with LIF.
Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.
WO 01/64239 WO 0164239PCT/AU01/00223
BIBLIOGRAPHY
1. Bernard, Mandel, T. and Mackay, IR., Experimental models of human autoimmune disease: overview and prototypes, in 71e autimmune diseases KI, N.a.M. Rose, 1K, Editor. 1992, Academic Press: San Diego. p. 47-106 2. Raine, Demyelinating diseases, in Textbook of Neuropatholgy, R.a.R. Davis, DM, Editor. 1990, Williams and Wilkins: Baltimore. p. 535-620 3. Ruuls, de Labie, Weber, Botman, Groenestein, R.J., Dijkstra, Olsson, van der Meide, J Immunol. 157(12):5721-31, 1996 4. Aharoni, Sela, Teitelbaum, J NeuroL 243(4 Suppi. p. SS- 13, 1996
Claims (3)
- 04-04-'06 12:23 FROM- T-761 P003/13 F-723 "<t 0 lB ipdade4MPOG -32- THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 1. Use of LIF for the manufacture of a medicament for the treatment and/or prophylaxis of experimental autoimmune encephalomyelitis, experimental autoimmune neuritis, encephalomyelitis, neuropathic acute demyelinating neuropathy, chronic inflammatory demyelinating polyneuropathy or progressive multi-focal leucoencephalopathy in a mammal. 2. A use according to claim I wherein the LIF is human LIF or humanized murine 3. A use according to claim I or 2 wherein the mammal is a human or a murine species. 4. A method for the treatment of prophylaxis of experimental autoimmune encephalomyelitis, experimental autoimmune neuritis, encephalomyelitis, neuropathic acute demyelinating neuropathy, chronic inflammatory demyelinating polyneuropathy or progressive multi-focal leucoencephalopathy in a small mammal said method comprising administering to said subject an effective amount of LIF. The method of claim 4 wherein the LIF is human LIF or humanized murine LIF.
- 6. The method of claim 4 or 5 wherein the mammal is a human or murine species.
- 7. The use of claim 1 or 2 or 3 or the method of claim 4 or 5 or 6 substantially as hereinbefore described with reference to the Figures and/or Examples. Dated this 4 t day of April, 2006 Amrad Corporation By DAVIES COLLISON CAVE Patent Attorneys for the Applicant COMS ID No: SBMI-03219713 Received by IP Australia: Time 12:29 Date 2006-04-04
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ5984 | 2000-03-03 | ||
| AUPQ5984A AUPQ598400A0 (en) | 2000-03-03 | 2000-03-03 | A method of treatment |
| AUPQ7810 | 2000-05-29 | ||
| AUPQ7810A AUPQ781000A0 (en) | 2000-05-29 | 2000-05-29 | A method of treatment |
| PCT/AU2001/000223 WO2001064239A1 (en) | 2000-03-03 | 2001-03-02 | A method of treatment |
| AU3713201A AU3713201A (en) | 2000-03-03 | 2001-03-02 | A method of treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006201457A Division AU2006201457A1 (en) | 2000-03-03 | 2006-04-06 | A method of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2001237132A1 AU2001237132A1 (en) | 2001-11-22 |
| AU2001237132B2 true AU2001237132B2 (en) | 2006-04-27 |
Family
ID=27153796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU3713201A Pending AU3713201A (en) | 2000-03-03 | 2001-03-02 | A method of treatment |
| AU2001237132A Ceased AU2001237132B2 (en) | 2000-03-03 | 2001-03-02 | A method of treatment |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU3713201A Pending AU3713201A (en) | 2000-03-03 | 2001-03-02 | A method of treatment |
Country Status (1)
| Country | Link |
|---|---|
| AU (2) | AU3713201A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991014443A1 (en) * | 1990-03-20 | 1991-10-03 | Amrad Corporation Limited | A method for regulating neuron development and maintenance |
| WO1996025929A1 (en) * | 1995-02-21 | 1996-08-29 | Takeda Chemical Industries, Ltd. | Use of helioxanthin as an enhancer of cell differentiation inducing factors |
| WO2000077029A1 (en) * | 1999-06-16 | 2000-12-21 | Myelos Corporation | Retro-inverso peptides derived from leukemia inhibitory factor |
-
2001
- 2001-03-02 AU AU3713201A patent/AU3713201A/en active Pending
- 2001-03-02 AU AU2001237132A patent/AU2001237132B2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991014443A1 (en) * | 1990-03-20 | 1991-10-03 | Amrad Corporation Limited | A method for regulating neuron development and maintenance |
| WO1996025929A1 (en) * | 1995-02-21 | 1996-08-29 | Takeda Chemical Industries, Ltd. | Use of helioxanthin as an enhancer of cell differentiation inducing factors |
| WO2000077029A1 (en) * | 1999-06-16 | 2000-12-21 | Myelos Corporation | Retro-inverso peptides derived from leukemia inhibitory factor |
Also Published As
| Publication number | Publication date |
|---|---|
| AU3713201A (en) | 2001-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12091441B2 (en) | Partial agonists of interleukin-2 | |
| Selmaj et al. | Anti—tumor necrosis factor therapy abrogates autoimmune demyelination | |
| JP3813440B2 (en) | Treatment method for patients with multiple sclerosis using consensus interferon | |
| KR100560085B1 (en) | Pharmaceutical Compositions Containing Long Pentraxine PT3 | |
| US20030171253A1 (en) | Methods and compositions relating to modulation of A20 | |
| US20130089515A1 (en) | Use of IL-12 and IL-12 Antagonists in the Treatment of Autoimmune Diseases | |
| US20070212372A1 (en) | Methods for the treatment and prophylaxis of demeyelinating disease | |
| Willenborg et al. | Cytokines in the pathogenesis and therapy of autoimmune encephalomyelitis and multiple sclerosis | |
| AU2001237132B2 (en) | A method of treatment | |
| WO1995021864A1 (en) | Antibodies which bind the g-csf receptor extracellular domain and methods of treatment | |
| AU2001237132A1 (en) | A method of treatment | |
| AU2006201457A1 (en) | A method of treatment | |
| JP7649923B2 (en) | GPC3-Targeted Antibody Interferon Alpha Fusion Protein and Uses Thereof | |
| US6497870B1 (en) | Therapeutic uses of il-1 receptor antagonist | |
| EP3124040B1 (en) | Il-6 for therapy of chemotherapy-induced neuropathy | |
| ES2226097T3 (en) | NNT-1 NEUROTROPHIC FACTOR. | |
| Vogels et al. | Interleukin-1 (IL-1)-induced resistance to bacterial infection: role of the type I IL-1 receptor | |
| JP2001518449A (en) | Apolipoprotein E / growth factor complex and uses thereof | |
| US6387875B1 (en) | Method of use for murine leukaemia inhibitory factor-binding protein (mLBP) | |
| AU700798B2 (en) | Antibodies which bind the G-CSF receptor extracellular domain and methods of treatment | |
| AU2011203356B2 (en) | IL6R/IL6 chimera for therapy of chemotherapy-induced peripheral neuropathy | |
| TW202413398A (en) | Interleukin-2 variants and their uses in treating cancers | |
| MXPA00001207A (en) | Methods for treatment of patients afflicted wih multiple sclerosis using consensus interferon | |
| KR20060136385A (en) | Medicament comprising inhibitors of long pentraxin ptx3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: AMRAD CORPORATION LIMITED Free format text: FORMER APPLICANT(S): THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |